Diabetes Update – Amputation Risk?

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Q: I am currently taking Invokan® (canagliflozin). I’ve heard that it might lead to an amputation. Should I stop taking it?

A: Recent research has shown a slight increase in amputations (most commonly at the level of the toe or middle of the foot) in people with diabetes and high cardiovascular risk who take canagliflozin. Over a year’s time, about 6 out of every 1,000 people who took canagliflozin had amputations, compared with about 3 out of every 1000 people who took a placebo (inactive pill). The risk of amputation may be higher for people who are already at risk for amputation, such as those with poor blood circulation to the legs, neuropathy (nerve damage), diabetic foot ulcers (sores), or a previous amputation.

At this time, it is unknown whether other “gliflozin” medications (dapagliflozin [Farxiga®], dapagliflozin/ metformin [Xigduo®], or empagliflozin [Jardiance®] also increase the risk of amputations. People who are taking these drugs (especially canagliflozin) should tell their healthcare provider right away if they develop new pain or tenderness, sores or ulcers, or infections of their feet or legs. You should not stop taking your diabetes medication unless your provider tells you to do so.

Rx Patient Connection. The Rx Consultant October 2017 Volume XXVI Number 9

More To Explore

What is The Rx Consultant?

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. All our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

For 30 years The Rx Consultant has operated independent of the pharmaceutical industry and has no commercial bias.

Join thousands of healthcare providers who enjoy the following benefits every month.

1. Drug Therapy Updates & Reviews

The eLibrary contains over 30 streamlined updates on drug therapy for the most common diseases. New articles are added every month – it is a continually expanding resource.

2. Continuing Education

The eLibrary includes 50+ hours of Pharmacology CE from an ACPE approved provider at no additional charge. Each article provides at least 1.5 hours of Pharmacology CE. Subscribers can take their tests online, score them immediately, then print or save their credit statements. Pharmacology CE tests can also be mailed, faxed, or even phoned in to The Rx Consultant office, and credit statements will be delivered by mail or fax.

3. Unlimited Access to our Resource Library, with:

  • Healthcare News

    The eLibrary includes a news column covering the developments that matter most to nurse practitioners and other front-line providers. You get a headline, the bottom line, and how it’s likely to affect your practice in a few short lines, then it’s on to the next news item. The news briefs are also available in print monthly as Rx News Connection.
  • Patient Education Pages

    Patient Q&A to sharpen your skills in educating patients and answering common questions.
  • Charts & Tables

    At-a-glance updates on drugs, doses, common side effects & interactions
  • Quick Facts

    Key facts organized for fast access both online and on handy reference cards.
  • The Bottom Line

    Our members suggest the topics and each issue undergoes a rigorous three month peer reviewed process. Our CE is different because we accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.

The Rx Consultant maintains a high standard for quality

And a rigorous system for content development that insures it. Every issue is written by an expert in the topic area, and then peer reviewed, fact-checked and edited to insure that the content is

  • Evidence-based
  • Non-Biased
  • Balanced
  • Timely
  • Accurate and
  • Useful for community practitioners

The Rx Consultant is completely independent of the pharmaceutical industry.

We accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.